Literature DB >> 35039967

Family experience of palliative sedation therapy: proportional vs. continuous deep sedation.

Kengo Imai1, Tatsuya Morita2, Masanori Mori2, Naosuke Yokomichi2, Toshihiro Yamauchi3, Satoru Miwa3, Satoshi Inoue3, Akemi Shirado Naito4, Kento Masukawa5, Yoshiyuki Kizawa6, Satoru Tsuneto7, Yasuo Shima8, Hiroyuki Otani9, Mitsunori Miyashita5.   

Abstract

PURPOSE: Some patients experience intense symptoms refractory to intensive palliative care, and palliative sedation is sometimes used. Palliative sedation may be classified into proportional and continuous deep sedation (CDS). The primary aim of this study was to compare family experience between families of patients who received proportional or CDS.
METHODS: A multicenter questionnaire survey was conducted involving bereaved families of cancer patients who received proportional or CDS based on a sedation protocol. Overall evaluation of sedation (satisfaction, family-perceived distress, appropriateness of timing, and patient distress) and 13-item family concerns, good death, satisfaction with care, depression, quality of care, unfinished business, and balance between symptom relief and maintaining communication were measured.
RESULTS: Among the 2120 patients who died, 222 patients received a continuous infusion of midazolam. A sedation protocol was used in 147 patients, and questionnaires were sent to 124 families. A total of 78 responses were finally returned (proportional, 58 vs. CDS, 20). There were no significant differences in the overall evaluation, family concerns, total score of good death, satisfaction, depression, or balance between symptom relief and maintaining communication. On the other hand, some quality of care items, i.e., relationship with medical staff (P < 0.01), physical care by nurses (P = 0.04), and coordination and consistency (P = 0.04), were significantly better in the CDS group than in the proportional sedation group. Family-reported unfinished business was also better in the CDS group, with marginal significance.
CONCLUSIONS: Family experience of CDS was not less favorable than proportional sedation, and actually rated more favorably for some elements of quality of care and unfinished business.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Continuous deep sedation; Experience; Family; Palliative sedation; Proportional sedation; Protocol

Mesh:

Substances:

Year:  2022        PMID: 35039967     DOI: 10.1007/s00520-021-06745-1

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  3 in total

1.  Continuous deep sedation in home palliative care units: case studies in the Florence area in 2000 and in 2003-2004.

Authors:  F Bulli; G Miccinesi; E Biancalani; M Fallai; M Mannocci; E Paci; M Piazza; C Tempestini; P Morino
Journal:  Minerva Anestesiol       Date:  2007-01-25       Impact factor: 3.051

Review 2.  Palliative pharmacological sedation for terminally ill adults.

Authors:  Elaine M Beller; Mieke L van Driel; Leanne McGregor; Shani Truong; Geoffrey Mitchell
Journal:  Cochrane Database Syst Rev       Date:  2015-01-02

3.  Development the Care Evaluation Scale Version 2.0: a modified version of a measure for bereaved family members to evaluate the structure and process of palliative care for cancer patient.

Authors:  Mitsunori Miyashita; Maho Aoyama; Misato Nakahata; Yuji Yamada; Mutsumi Abe; Kazuhiro Yanagihara; Akemi Shirado; Mariko Shutoh; Yoshiaki Okamoto; Jun Hamano; Aoi Miyamoto; Saki Yoshida; Kazuki Sato; Kei Hirai; Tatsuya Morita
Journal:  BMC Palliat Care       Date:  2017-01-23       Impact factor: 3.234

  3 in total
  1 in total

1.  Engaging African American family Caregivers in Developing a Culturally-responsive Interview Guide: A Multiphase Process and Approach.

Authors:  Shena Gazaway; Marie A Bakitas; Ronit Elk; Nwamaka D Eneanya; J Nicholas Dionne-Odom
Journal:  J Pain Symptom Manage       Date:  2022-03-03       Impact factor: 5.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.